Immunoregulatory Intestinal Microbiota and COVID-19 in Patients with Type Two Diabetes: A Double-Edged Sword
dc.contributor.author | Petakh, Pavlo | |
dc.contributor.author | Kamyshna, Iryna | |
dc.contributor.author | Nykyforuk, Andriy | |
dc.contributor.author | Yao, Rouan | |
dc.contributor.author | Imbery, John Franklin | |
dc.contributor.author | Oksenych, Valentyn | |
dc.contributor.author | Korda, Mykhaylo | |
dc.contributor.author | Kamyshnyi, Aleksandr | |
dc.date.accessioned | 2023-01-31T09:39:50Z | |
dc.date.available | 2023-01-31T09:39:50Z | |
dc.date.created | 2022-05-03T12:32:00Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Viruses. 2022, 14 (3), . | en_US |
dc.identifier.issn | 1999-4915 | |
dc.identifier.uri | https://hdl.handle.net/11250/3047301 | |
dc.description.abstract | Coronavirus disease 2019, or COVID-19, is a major challenge facing scientists worldwide. Alongside the lungs, the system of organs comprising the GI tract is commonly targeted by COVID-19. The dysbiotic modulations in the intestine influence the disease severity, potentially due to the ability of the intestinal microbiota to modulate T lymphocyte functions, i.e., to suppress or activate T cell subpopulations. The interplay between the lungs and intestinal microbiota is named the gut–lung axis. One of the most usual comorbidities in COVID-19 patients is type 2 diabetes, which induces changes in intestinal microbiota, resulting in a pro-inflammatory immune response, and consequently, a more severe course of COVID-19. However, changes in the microbiota in this comorbid pathology remain unclear. Metformin is used as a medication to treat type 2 diabetes. The use of the type 2 diabetes drug metformin is a promising treatment for this comorbidity because, in addition to its hypoglycemic action, it can increase amount of intestinal bacteria that induce regulatory T cell response. This dual activity of metformin can reduce lung damage and improve the course of the COVID-19 disease. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | MDPI | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Immunoregulatory Intestinal Microbiota and COVID-19 in Patients with Type Two Diabetes: A Double-Edged Sword | en_US |
dc.title.alternative | Immunoregulatory Intestinal Microbiota and COVID-19 in Patients with Type Two Diabetes: A Double-Edged Sword | en_US |
dc.type | Peer reviewed | en_US |
dc.type | Journal article | en_US |
dc.description.version | publishedVersion | en_US |
dc.source.pagenumber | 21 | en_US |
dc.source.volume | 14 | en_US |
dc.source.journal | Viruses | en_US |
dc.source.issue | 3 | en_US |
dc.identifier.doi | 10.3390/v14030477 | |
dc.identifier.cristin | 2020937 | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 |